Sunshine Bizerma获得两种新抗生素在加拿大的营销权

2025-03-24 20:19

Sunshine Biopharma (NASDAQ:SBFM) Monday said that it has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada.
The company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval.
According to BioSpace, the global antibiotics market size in 2024 was estimated at $53.9 billion and is expected to reach approximately $85.8 billion by 2033, representing a compound annual growth rate of 5.3%.

More on Sunshine Biopharma